AI Article Synopsis
- The study examined the impact of menopausal hormone therapy (MHT) on the severity of COVID-19 in women, finding a slight association with reduced mortality and shorter hospital stays for those using MHT.
- The protective effects were more notable for estrogen-only and estrogen-plus-progestin therapies compared to progestin-only therapy, although these differences weren't statistically significant.
- It’s advised that women with COVID-19 can continue their MHT, but more clinical trials are necessary to fully understand its potential therapeutic effects on the virus.
Article Abstract
Whether menopausal hormone therapy (MHT) lessens the severity of COVID-19 among women is unclear. Leveraging a U.S. national COVID-19 cohort and a cross-sectional analysis, we found MHT use was marginally associated with a lower risk of mortality (odds ratio [OR] 0.73, 95 % CI 0.53-1.01) and significantly associated with a lower risk of prolonged hospital stay (0.7, 0.49-0.99) among inpatient women. When stratifying by MHT type, estrogen-only and estrogen-plus-progestin therapies had a more prominent protective effect than progestin-only therapy, although this difference did not achieve statistical significance. Women with COVID-19 can continue to use MHT. Clinical trials are needed to evaluate MHT's therapeutic effect on COVID-19, especially in terms of severity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633103 | PMC |
| http://dx.doi.org/10.1016/j.maturitas.2022.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!